丹纳赫Q3收入增长4%，牙科业务Envista将上市
分析测试百科网讯 近日，丹纳赫宣布了其2019年第三季度的业绩。截至2019年9月27日的第三季度，丹纳赫净利润为6.484亿美元，摊薄后每股收益为0.89美元，较2018年同期下降4.5%。
2019年第三季度，集团收入同比增长4.0%，达到50亿美元，Non-GAAP核心收入增长5.0%。若不包括Envista (NVST)的牙科业务，2019年第三季度集团的Non-GAAP核心收入增长为6.0%。对于2019年第四季度，该公司预计摊薄后的每股净收益将在1.06美元至1.09美元之间，Non-GAAP调整后的摊薄后每股净收益将在1.32美元至1.35美元之间。
对于2019年全年，集团目前预计摊薄后的每股净利润将在3.38美元至3.41美元之间，而此前的预期为3.38美元至3.43美元。丹纳赫预计，2019年Non-GAAP调整后摊薄后的每股净利润为4.74美元至4.77美元。按GAAP计算的每股收益和Non-GAAP计算的每股收益都包括了该公司不再持有的Envista 19.4%的非控股股权带来的稀释。
丹纳赫总裁兼首席执行官Thomas P. Joyce, Jr.表示:“我们对第三季度的强劲表现感到满意，因为我们又实现了一个季度5%的核心收入增长和稳健的利润率增长。我们相信，我们在创新和商业举措方面的持续投资将有助于我们在许多业务领域继续建立可持续的竞争优势。本季度，我们在最近的两次投资组合调整上也取得了显著进展。9月18日，我们的牙科业务——Envista，开始作为一家上市公司进行交易。同时，我们也取得了几个与GE生物制药收购相关的重要进展。本周早些时候，我们宣布了将某些业务出售给赛多利斯的计划。此外，我们在9月份筹集了约68亿美元的，用于此次收购的资金。”
| CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (unaudited) | ||||||||
| $ and shares in millions, except per share amounts | ||||||||
| Three-Month Period Ended | Nine-Month Period Ended | |||||||
| September 27,2019 | September 28,2018 | September 27,2019 | September 28,2018 | |||||
| Sales | $ | 5,037.30 | $ | 4,853.10 | $ | 15,073.80 | $ | 14,529.50 |
| Cost of sales | -2,228.90 | -2,162.60 | -6,670.00 | -6,378.30 | ||||
| Gross profit | 2,808.40 | 2,690.50 | 8,403.80 | 8,151.20 | ||||
| Operating costs: | ||||||||
| Selling, general and administrative expenses | -1,654.70 | -1,558.60 | -5,009.90 | -4,798.40 | ||||
| Research and development expenses | -318.9 | -301.2 | -951.5 | -911.6 | ||||
| Operating profit | 834.8 | 830.7 | 2,442.40 | 2,441.20 | ||||
| Nonoperating income (expense): | ||||||||
| Other income, net | 4.4 | 9.1 | 15.9 | 25.2 | ||||
| Interest expense | -26.3 | -41.3 | -70.2 | -123.6 | ||||
| Interest income | 30.1 | 2.8 | 72 | 6.7 | ||||
| Earnings before income taxes | 843 | 801.3 | 2,460.10 | 2,349.50 | ||||
| Income taxes | -169.1 | -137.6 | -721.1 | -445.4 | ||||
| Net earnings | 673.9 | 663.7 | 1,739.00 | 1,904.10 | ||||
| Less: net earnings attributable to noncontrolling interests | -5.9 | — | -5.9 | — | ||||
| Net earnings attributable to Danaher stockholders | 668 | 663.7 | 1,733.10 | 1,904.10 | ||||
| Mandatory convertible preferred stock dividends | -19.6 | — | -48.8 | — | ||||
| Net earnings attributable to common stockholders | $ | 648.4 | $ | 663.7 | $ | 1,684.30 | $ | 1,904.10 |
| Net earnings per common share: | ||||||||
| Basic | $ | 0.9 | $ | 0.95 | $ | 2.36 | $ | 2.72 |
| Diluted | $ | 0.89 | $ | 0.93 | $ | 2.32 | $ | 2.68 |
| Average common stock and common equivalent shares | ||||||||
| outstanding: | ||||||||
| Basic | 718.8 | 701.4 | 714.7 | 700.1 | ||||
| Diluted | 729.3 | 710.6 | 725.2 | 709.9 | ||||
| This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com). | ||||||||
